Progress in the treatment of neovascular age-related macular degeneration

Age-related macular degeneration(ARMD)is an important cause of visual impairment in people over 65 years old in western countries. It is the third leading cause of blindness in China and mainly affects central visual acuity. Vascular endothelial growth factor(VEGF)plays an important role in the pathogenesis of ARMD. Currently, intravitreous injection of anti-VEGF agents has been considered as the first-line treatment for ARMD. However, some patients still need repeated injection, or response negatively to anti-VEGF agents. Therefore, it is necessary to explore novel therapy to improve clinical outcomes and provide insights for neovascular ARMD treatment